Radiopharm Theranostics Limited American Depositary Shares (RADX) — Cash Flow-to-Debt Ratio
Radiopharm Theranostics Limited American Depositary Shares (RADX) has a Cash Flow-to-Debt Ratio of -0.22x as of December 2024, meaning its operating cash flow of $-8.74 Million could theoretically repay 0% of its total liabilities ($40.45 Million) in one year. See RADX net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Radiopharm Theranostics Limited American Depositary Shares Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for Radiopharm Theranostics Limited American Depositary Shares across 4 annual periods. Also explore net asset momentum of Radiopharm Theranostics Limited American to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Radiopharm Theranostics Limited American Depositary Shares (2022–2025)
Year-by-year debt coverage analysis for Radiopharm Theranostics Limited American Depositary Shares. For market capitalisation and broader financial context, see market value of Radiopharm Theranostics Limited American.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.84x | $-36.65 Million | $43.61 Million | ▼ -63.4% |
| 2024 | -0.51x | $-22.98 Million | $44.68 Million | ▲ +34.9% |
| 2023 | -0.79x | $-23.20 Million | $29.37 Million | ▼ -62.7% |
| 2022 | -0.49x | $-9.92 Million | $20.42 Million | — |